FI112946B - 4-hydroxi-1-oxo-1,2-dihydro-pyridazino[4,5-b]-kinolin-5-oxidderivat, deras framställning, och deras användning som glycinantagonister - Google Patents
4-hydroxi-1-oxo-1,2-dihydro-pyridazino[4,5-b]-kinolin-5-oxidderivat, deras framställning, och deras användning som glycinantagonister Download PDFInfo
- Publication number
- FI112946B FI112946B FI990134A FI990134A FI112946B FI 112946 B FI112946 B FI 112946B FI 990134 A FI990134 A FI 990134A FI 990134 A FI990134 A FI 990134A FI 112946 B FI112946 B FI 112946B
- Authority
- FI
- Finland
- Prior art keywords
- quinoline
- oxo
- hydroxy
- dihydropyridazino
- oxide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (15)
1. Ur en grupp av 4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-derivat vald förening med följande formel: o « 8 Ji Y ·νγ ^ ^NH R1 7 N O- OH 5 där Rl och R2 har valts ur gruppen väte, halogen och metoxi, eller där Rl och R2 tillsammans bildar metylendioxi eller ett farmaceutiskt godtagbart salt därav.
2. Förening enligt patentkrav 1, där saltet har valts ur en grupp av dess kolin- och 4-tetrametylammoniumsalt.
3. Förening enligt patentkrav 1, som valts ur en grupp bestäende av 10 4-hydroxi-l-oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 8-klor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 8-brom-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 8-fluor-4-hydroxi-1-oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 7.8- diklor-4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, t 15 7-brom-8-klor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid och 7- klor-8-brom-4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid samt • ett farmaceutiskt godtagbart salt av vilken som heist av ovan nämnda förening.
4. Förening enligt patentkrav 2, som valts ur en grupp av ett 4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, 20 8-klor-4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, 8- brom-4-hydroxi- 1-oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, ; 8-fluor-4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, 7.8- diklor-4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, 7-brom-8-klor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid- ' ;1' 25 kolinsalt och ; : 7-klor-8-brom-4-hydroxi- 1-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid- : ; kolinsalt. 39 112946
5. Farmaceutisk sammansättning som innehäller som aktivt ämne en effektiv glycinp-antagonistisk mängd av en förening enligt patentkrav 1, samt en farmaceu-tiskt godtagbar bärare eller diluent.
6. Farmaceutisk sammansättning som innehäller som aktivt ämne en effektiv 5 glycinp-antagonistisk mängd av en förening enligt patentkrav 1 som kolinsalt, samt en farmaceutiskt godtagbar bärare eller diluent.
7. Farmaceutisk sammansättning som innehäller som aktivt ämne en effektiv glycinp-antagonistisk mängd av en förening som valts ur en grupp bestäende av 4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 10 8-klor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 8-brom-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 8-fluor-4-hydroxi-l-oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 7,8-diklor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 7-brom-8-klor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid och 15 7-klor-8-brom-4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid samt ett farmaceutiskt godtagbart sait av vilken som heist av ovan nämnda förening.
8. Farmaceutisk sammansättning som innehäller som aktivt ämne en effektiv glycinp-antagonistisk mängd av en förening som valts ur en grupp bestäende av 4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, ,« 20 8-klor-4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, : 8-brom-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, : 8-fluor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, ; 7,8-diklor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, , 7-brom-8-klor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolin- 25 sait och 7-klor-8-brom-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt.
9. Användning av en förening enligt patentkrav 1 vid framställning av medicin mot exitotoxicitet och neurologiska stömingar relaterade tili felfunktion i den 30 glutamatergiska nervförmedlingen. 40 112946
10. Användning av ett kolinsalt av en forening enligt patentkrav 2 vid framställ-ning av medicin mot neurologiska störningar relaterade tili felfunktion i nervför-medlingen.
11. Användning av en forening enligt patentkrav 1 vid framställning av medicin 5 mot exitotoxicitet och neurologiska störningar relaterade tili felfunktion i den glutamatergiska nervförmedlingen, vilken forening har valts ur en grupp bestäende av 4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 8-klor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 10 8-brom-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 8-fluor-4-hydroxi-1-oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 7.8- diklor-4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid, 7-brom-8-klor-4-hydroxi-l-oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid och 7- klor-8-brom-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid eller 15 ett farmaceutiskt godtagbart sait av vilken som heist av ovan nämnda forening.
12. Användning av en forening enligt patentkrav 2 vid framställning av medicin mot exitotoxicitet och neurologiska störningar relaterade tili felfunktion i den glutamatergiska nervförmedlingen, vilken forening har valts ur en grupp bestäende av ett 20 4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, 8- klor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, 8-brom-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, 8-fluor-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b] -kinolin-5-oxid-kolinsalt, 7.8- diklor-4-hydroxi- 1-oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt, 25 7-brom-8-klor-4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid och 7-klor-8-brom-4-hydroxi-1 -oxo-1,2-dihydropyridazino[4,5-b]-kinolin-5-oxid-kolinsalt.
13. Förfarande för framställning av 4-hydroxi-1-oxo-l,2-dihydropyridazino[4,5-b]-kinolin-5-oxid (5) 41 112946 O O y^kX R2 0 vilket förfarande innefattar ett steg där dimetyl-kinolin-2,3-dikarboxylat-l-oxid (3) 0' D 1 I \y<;^;V\Y^N'XNv^C00Me R2 omvandlas till ett hydrazinsalt (4) O' oh.h2nnh2 ysJyl, 5 o ' genom reaktion med hydrazinhydrat och det resulterande hydrazinsaltet (4) hydroly- ; seras för framställning av önskad 4-hydroxi-l-oxo-l,2-dihydropyridazino[4,5-b]- kinolin-5-oxid (5).
14. Förfarande enligt patentkrav 13, där den sälunda erhällna 4-hydroxi-l-oxo-l,2-10 dihydropyridazino[4,5-b]-kinolin-5-oxiden (5) omvandlas tili sitt kolinsalt (6) 42 112946 0’ ON+Me3CH2CH2OH O med reaktion av kinolinhydroxid. *
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68634696 | 1996-07-25 | ||
| US08/686,346 US5776935A (en) | 1996-07-25 | 1996-07-25 | Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission |
| EP9704057 | 1997-07-25 | ||
| PCT/EP1997/004057 WO1998004556A1 (en) | 1996-07-25 | 1997-07-25 | Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI990134A0 FI990134A0 (sv) | 1999-01-25 |
| FI990134A FI990134A (sv) | 1999-03-24 |
| FI112946B true FI112946B (sv) | 2004-02-13 |
Family
ID=24755940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI990134A FI112946B (sv) | 1996-07-25 | 1999-01-25 | 4-hydroxi-1-oxo-1,2-dihydro-pyridazino[4,5-b]-kinolin-5-oxidderivat, deras framställning, och deras användning som glycinantagonister |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5776935A (sv) |
| EP (1) | EP0931081B1 (sv) |
| JP (1) | JP3595342B2 (sv) |
| KR (1) | KR100598206B1 (sv) |
| CN (1) | CN1093860C (sv) |
| AR (1) | AR004158A1 (sv) |
| AT (1) | ATE224894T1 (sv) |
| AU (1) | AU719993B2 (sv) |
| BR (1) | BR9710569A (sv) |
| CA (1) | CA2261923C (sv) |
| CZ (1) | CZ289293B6 (sv) |
| DE (1) | DE69715893T2 (sv) |
| DK (1) | DK0931081T3 (sv) |
| EA (1) | EA001711B1 (sv) |
| ES (1) | ES2180041T3 (sv) |
| FI (1) | FI112946B (sv) |
| GE (1) | GEP20022801B (sv) |
| HK (1) | HK1020193A1 (sv) |
| HU (1) | HU223780B1 (sv) |
| IL (1) | IL128225A (sv) |
| LT (1) | LT4591B (sv) |
| LV (1) | LV12260B (sv) |
| NO (1) | NO310820B1 (sv) |
| PL (1) | PL189572B1 (sv) |
| PT (1) | PT931081E (sv) |
| SI (1) | SI9720048B (sv) |
| SK (1) | SK283536B6 (sv) |
| TW (1) | TW402605B (sv) |
| UA (1) | UA63911C2 (sv) |
| WO (1) | WO1998004556A1 (sv) |
| ZA (1) | ZA976612B (sv) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030176435A1 (en) * | 2002-12-17 | 2003-09-18 | Brown Dean Gordon | Compounds and methods for the treatment of pain |
| US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
| EP1427404A4 (en) * | 2001-08-20 | 2005-10-26 | Maiken Nedergaard | TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS |
| EP1298581A1 (fr) * | 2001-09-27 | 2003-04-02 | C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa | Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal |
| US7105185B2 (en) | 2001-10-03 | 2006-09-12 | Herbalscience, Llc | Kavalactone profile |
| US7291352B2 (en) | 2001-10-03 | 2007-11-06 | Herbalscience Llc | Methods and compositions for oral delivery of Areca and mate' or theobromine |
| US7001620B2 (en) | 2001-10-03 | 2006-02-21 | Herbal Science, Llc | Kavalactone product |
| US7037524B2 (en) * | 2001-10-03 | 2006-05-02 | Herbalscience, Llc | Oral delivery of a botanical |
| US20050069596A1 (en) * | 2001-10-03 | 2005-03-31 | Gow Robert T. | Compositions and methods comprising kava and anti-anxiety compounds |
| US7029707B2 (en) * | 2001-10-03 | 2006-04-18 | Herbalscience, Llc | Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same |
| US20050037025A1 (en) * | 2002-10-03 | 2005-02-17 | Gow Robert T. | Methods and compositions comprising kava and mate' or theobromine |
| US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| US7294353B2 (en) * | 2003-10-24 | 2007-11-13 | Herbalscience, Llc | Methods and compositions comprising ilex |
| CN1917892A (zh) * | 2003-10-24 | 2007-02-21 | 草本制药科学有限责任公司 | 包含冬青的方法和组合物 |
| SG161256A1 (en) * | 2005-04-08 | 2010-05-27 | Abbott Lab | Oral pharmaceutical formulations comprising fenofibric acid and/or its salts |
| BRPI0815957A2 (pt) * | 2007-09-20 | 2019-09-24 | Cortex Pharma Inc | "composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas" |
| EP2264035A1 (en) * | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | Glycine B antagonists |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| AU2018284335A1 (en) | 2017-06-12 | 2020-01-30 | Glytech Llc. | Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists |
| USD895157S1 (en) | 2018-03-06 | 2020-09-01 | IsoTruss Indsutries LLC | Longitudinal beam |
| CN109912503B (zh) * | 2019-04-01 | 2022-04-08 | 江南大学 | 一种2,3-二酰基喹啉类化合物的合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9208511D0 (en) * | 1991-05-09 | 1992-06-03 | Ici Plc | Compounds |
| US5597922A (en) * | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
-
1996
- 1996-07-25 US US08/686,346 patent/US5776935A/en not_active Expired - Fee Related
-
1997
- 1997-07-23 TW TW086110479A patent/TW402605B/zh not_active IP Right Cessation
- 1997-07-24 ZA ZA9706612A patent/ZA976612B/xx unknown
- 1997-07-25 UA UA99021084A patent/UA63911C2/uk unknown
- 1997-07-25 AR ARP970103380A patent/AR004158A1/es active IP Right Grant
- 1997-07-25 DK DK97918944T patent/DK0931081T3/da active
- 1997-07-25 PT PT97918944T patent/PT931081E/pt unknown
- 1997-07-25 CA CA002261923A patent/CA2261923C/en not_active Expired - Fee Related
- 1997-07-25 SK SK103-99A patent/SK283536B6/sk unknown
- 1997-07-25 ES ES97918944T patent/ES2180041T3/es not_active Expired - Lifetime
- 1997-07-25 CN CN97197534A patent/CN1093860C/zh not_active Expired - Fee Related
- 1997-07-25 SI SI9720048A patent/SI9720048B/sl not_active IP Right Cessation
- 1997-07-25 WO PCT/EP1997/004057 patent/WO1998004556A1/en active IP Right Grant
- 1997-07-25 AT AT97918944T patent/ATE224894T1/de not_active IP Right Cessation
- 1997-07-25 HU HU9903104A patent/HU223780B1/hu active IP Right Grant
- 1997-07-25 EA EA199900161A patent/EA001711B1/ru not_active IP Right Cessation
- 1997-07-25 AU AU42969/97A patent/AU719993B2/en not_active Ceased
- 1997-07-25 KR KR1019997000627A patent/KR100598206B1/ko not_active IP Right Cessation
- 1997-07-25 GE GEAP19974684A patent/GEP20022801B/en unknown
- 1997-07-25 PL PL97331323A patent/PL189572B1/pl not_active IP Right Cessation
- 1997-07-25 CZ CZ1999201A patent/CZ289293B6/cs unknown
- 1997-07-25 EP EP97918944A patent/EP0931081B1/en not_active Expired - Lifetime
- 1997-07-25 DE DE69715893T patent/DE69715893T2/de not_active Expired - Fee Related
- 1997-07-25 BR BR9710569A patent/BR9710569A/pt not_active Application Discontinuation
- 1997-07-25 IL IL12822597A patent/IL128225A/xx not_active IP Right Cessation
- 1997-07-25 JP JP50849998A patent/JP3595342B2/ja not_active Expired - Fee Related
-
1999
- 1999-01-22 NO NO19990306A patent/NO310820B1/no unknown
- 1999-01-22 LV LVP-99-14A patent/LV12260B/en unknown
- 1999-01-25 LT LT99-007A patent/LT4591B/lt not_active IP Right Cessation
- 1999-01-25 FI FI990134A patent/FI112946B/sv active
- 1999-11-02 HK HK99104938A patent/HK1020193A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI112946B (sv) | 4-hydroxi-1-oxo-1,2-dihydro-pyridazino[4,5-b]-kinolin-5-oxidderivat, deras framställning, och deras användning som glycinantagonister | |
| US8686002B2 (en) | Heterocyclic compounds and their use as binding partners for 5-HT5 receptors | |
| TW200815432A (en) | Pyrazolopyrimidines, a process for their preparation and their use as medicine | |
| JP3319762B2 (ja) | 新規インドール―２，３―ジオン―３―オキシム誘導体 | |
| EP0581106B1 (en) | Substituted aminothienopyridines, a process for their preparation and their use as medicaments | |
| AU2023266373A1 (en) | Kv7 channel activators compositions and methods of use | |
| Zarghi et al. | Synthesis and pharmacological evaluation of new 2-substituted-5-{2-[(2-halobenzyl) thio) phenyl}-1, 3, 4-oxadiazoles as anticonvulsant agents | |
| HUT72501A (en) | Derivatives of 5h,10h-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, preparation thereof and medicaments containing them | |
| CA3178966A1 (en) | N-(phenylaminocarbonyl) tetrahydro-isoquinolines and related compounds as modulators of gpr65 | |
| CN117088867A (zh) | 可吸入型芳环并噻嗪及类似物、含其的药物组合物及其在抗炎、抗肿瘤中的应用 | |
| CN109890823A (zh) | 稠合氮杂环化合物及其作为ampa受体调节剂的用途 | |
| AU741162B2 (en) | New 2,3-benzodiazepine derivatives | |
| Nishijima et al. | Synthesis and diuretic activity of 2, 3-dihydro-4 (1H)-quinolinone 4-oxime-O-sulfonic acid derivatives | |
| US20130116270A1 (en) | Novel compounds | |
| AU5749200A (en) | Chromeno(4,3,2-de)isoquinolines as potent dopamine receptor ligands | |
| WO2024056005A1 (zh) | 多并环类化合物及其用途 | |
| Rashed | Syntheses and structure-activity relationships of novel P2X3 receptor antagonists | |
| JP2023531097A (ja) | テトラヒドロイソキノリン類誘導体の塩、その製造方法及びその医薬学的応用 | |
| Barnard | Synthesis and profiling of antimalarial side-chain modified pyrido [1, 2-a] benzimidazoles | |
| Liszkiewicz et al. | Synthesis and anxiolytic activity of 1-phenyl-2-(4-aryl-1, 3, 4, 5-tetrahydropyrido [2, 3-b][1, 4] diazepin-2-ylidene)-ethanone | |
| CN110139855A (zh) | 新型的氘代脲类化合物 | |
| KR19990071254A (ko) | Nmda 수용체 길항제로 작용하는 4-(3-치환-2-옥소 및 2-티옥소-1,3-옥사졸리딘-5-일메톡시)-퀴놀린-2-카복실산 유도체 |